TABLE 1.

STUDIES OF ISAEs IN PATIENTS RECEIVING FOSAPREPITANT VIA PERIPHERAL IV ACCESS

STUDY	SAMPLE AND PATIENT POPULATION	ISAE INCIDENCE	POSSIBLE RISK FACTORS FOR ISAE IDENTIFIED
Chau et al., 2019	122 patients receiving any outpatient chemotherapy (285 infusions)	6%	Concentration of fosaprepitant; length of infusion
Gonçalves et al., 2017	57 patients receiving IV fosaprepitant (105 infusions)	40%	First time administration of fosaprepitant older age; IV placed in hand or wrist
Hegerova et al., 2014	64 patients with breast cancer	9%	Doxorubicin/cyclophosphamide administration
Leal et al., 2014	148 patients receiving doxorubicin/cydophosphamide	35%	–
Lundberg et al., 2014	150 patients receiving any outpatient chemotherapy (333 infusions)	15%	IV placed in hand; IV fluid rate less than 100 ml per hour; younger age
Sato et al., 2014	56 patients receiving anthracycline (159 infusions)	67%	Doxorubicin/cyclophosphamide administration

ISAE–infusion site adverse event